Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Budget to Support Development of Unapproved Drugs, Indications Cut to ¥10 Bil.
October 19, 2009
- HSTTC Licenses Tumor Markers to TransGenic
October 19, 2009
- Korosho's Supplementary Budget Cut by ¥435.9 Bil.
October 19, 2009
- TOPICS 2 articles
October 19, 2009
- Korosho to Reshuffle CDFS's 1st, 2nd Committees on Drugs Next April
October 19, 2009
- Erbitux's Efficacy Correlated with KRAS Gene Mutation in Japanese Patients as Well
October 19, 2009
- Additional Safety Information to Be Provided on Obescare
October 19, 2009
- GSK, Novartis Contract with Korosho to Supply Flu Vaccines
October 19, 2009
- Astellas to Apply for IBS in Women as Addn'l Indication for Irribow
October 19, 2009
- Some Healthcare Professionals Don't Recommend Use of Relief System to Their Patients to Save Time
October 19, 2009
- Terumo Applies for Left Ventricular Assist System
October 19, 2009
- BioJapan 2009
October 19, 2009
- Multaq Recommended for Approval in the EU: sanofi-aventis
October 19, 2009
- JPMA to Stress Value of New Drugs on TV
October 19, 2009
- Mylan to Develop Cysteamine, Zeria Oral Phosphate
October 19, 2009
- Takeda Introduces "Mutual Consent System" for Decision Making
October 19, 2009
- Disappointment Prevails at JPMA Seminar on Development of Unapproved Drugs
October 19, 2009
- Kowa Licenses Livalo to Algorithm in the Middle East, North Africa
October 19, 2009
- Korosho to Continue to Support Development of Unapproved Drugs via Non-budgetary Measures
October 19, 2009
- Sanwa Kagaku Licenses FYX-051 from Fuji Yakuhin
October 19, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…